ETON — Eton Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1710340 ·
Last close
$59.18
Market Cap
$1.69B
52W High
$66.37
52W Low
$14.27
ADV30
547,851
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 37,589,000 | 25,413,000 | 12,794,000 | 11,578,000 | 115,807,000 | 26,845,000 | 69,222,000 |
| Mar 2026 | 24,266,000 | 14,735,000 | 2,414,000 | 1,554,000 | 97,710,000 | 19,661,000 | 67,095,000 |
| Dec 2025 | 21,281,000 | 13,100,000 | 2,464,000 | 1,483,000 | 92,114,000 | 25,942,000 | 65,960,000 |
| Sep 2025 | 22,459,000 | 7,855,000 | -1,363,000 | -1,927,000 | 104,510,000 | 37,121,000 | 81,384,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$15,839,000
Investing CF
$-15,408,000
Financing CF
$1,810,000
CapEx
$-23,256,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.07
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-110,940,000
Inventory
$14,467,000
Receivables
$13,408,000
ST Investments
—
EBIT TTM
$2,040,000
Pretax Income TTM
$-1,486,000
Interest Exp TTM
$3,504,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$105,595,000
EBITDA
$25,178,000
Free Cash Flow
$6,581,250
Enterprise Value
$1,633,905,408
Total Cash
$26,845,000
Total Debt
$29,225,000
Shares Out
28,583,135
Trailing EPS
$0.39
Book Value
$1.65
ROE
36.0%
ROA
11.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 79,950,000 | -844,000 | -4,601,000 | 92,114,000 | 65,960,000 | 26,154,000 | 10,524,000 |
| Dec 2024 | 39,011,000 | -2,597,000 | -3,823,000 | 76,123,000 | 51,695,000 | 24,428,000 | 969,000 |
| Dec 2023 | 31,642,000 | -1,192,000 | -936,000 | 31,740,000 | 16,263,000 | 15,477,000 | 6,815,000 |
| Dec 2022 | 21,251,000 | -8,260,000 | -9,021,000 | 25,030,000 | 11,952,000 | 13,078,000 | 4,821,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.58
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $40.00 · spot: $59.18 · call volume: 33 · put volume: 63
Expected Move to 2026-11-20:
±$13.93
(23.54%) —
implied range
$45.25 –
$73.11
· ATM straddle on $60.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OCUL | OCULAR THERAPEUTIX, INC | $1.68B | $7.66 | — |
| ANIP | ANI PHARMACEUTICALS INC | $1.72B | $74.83 | — |
| NBTX | Nanobiotix S.A. | $1.66B | $32.60 | — |
| STOK | Stoke Therapeutics, Inc. | $1.65B | $25.50 | — |
| GHRS | GH Research PLC | $1.61B | $23.42 | — |
News headlines (Yahoo Finance, 1h cache)
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
2026-09-28 10:50 · Yahoo
Jim Cramer Explains Mad Money Caller How to Handle Eton Pharmaceuticals (ETON)
2026-08-28 18:39 · Yahoo
Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference
2026-08-27 10:50 · Yahoo
Three Biotech Stocks Stick Out With Their Stellar Charts
2026-08-21 16:09 · Yahoo
Eton Pharmaceuticals (ETON) Q2 2026 Earnings Call Transcript
2026-08-20 23:27 · Yahoo
Is Eton Pharmaceuticals (ETON) Fully Priced On Strong Q2 Results And Raised Guidance?
2026-08-15 04:20 · Yahoo
Why Eton Pharmaceuticals Is Top of the Class Today
2026-08-14 18:58 · Yahoo
This Analyst Believes Eton Pharma’s Raised Guidance Is ‘Conservative’ – ETON Stock Heads For Best Ever Day
2026-08-14 17:30 · Yahoo
Eton Pharmaceuticals Inc (ETON) (Q2 2026) Earnings Call Highlights: Record Revenue and ...
2026-08-14 05:02 · Yahoo
Eton Pharmaceuticals Q2 Earnings Call Highlights
2026-08-14 00:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.